22.34
Novocure Ltd stock is traded at $22.34, with a volume of 305.68K.
It is down -2.29% in the last 24 hours and down -22.77% over the past month.
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
See More
Previous Close:
$22.93
Open:
$22.81
24h Volume:
305.68K
Relative Volume:
0.27
Market Cap:
$2.48B
Revenue:
$577.74M
Net Income/Loss:
$-149.78M
P/E Ratio:
-15.96
EPS:
-1.4
Net Cash Flow:
$-78.21M
1W Performance:
-8.63%
1M Performance:
-22.77%
6M Performance:
+16.63%
1Y Performance:
+49.76%
Novocure Ltd Stock (NVCR) Company Profile
Name
Novocure Ltd
Sector
Industry
Phone
44 (0)15 3475 6700
Address
NO. 4 THE FORUM, ST. HELIER
Compare NVCR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
NVCR
Novocure Ltd
|
22.34 | 2.48B | 577.74M | -149.78M | -78.21M | -1.40 |
![]()
ABT
Abbott Laboratories
|
128.84 | 222.39B | 41.95B | 13.40B | 6.49B | 7.65 |
![]()
BSX
Boston Scientific Corp
|
105.39 | 154.78B | 15.91B | 1.79B | 1.89B | 1.21 |
![]()
SYK
Stryker Corp
|
391.86 | 150.99B | 22.60B | 2.99B | 3.49B | 7.76 |
![]()
MDT
Medtronic Plc
|
89.85 | 116.46B | 33.00B | 4.29B | 5.50B | 3.27 |
![]()
EW
Edwards Lifesciences Corp
|
71.04 | 41.87B | 6.60B | 4.16B | 490.10M | 6.93 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-02-24 | Upgrade | Evercore ISI | In-line → Outperform |
Oct-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
Nov-20-23 | Resumed | JP Morgan | Neutral |
Aug-28-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
Aug-08-23 | Upgrade | Piper Sandler | Neutral → Overweight |
Aug-04-23 | Initiated | SVB Securities | Outperform |
Jul-31-23 | Upgrade | Evercore ISI | Underperform → In-line |
Jun-07-23 | Upgrade | Wedbush | Underperform → Neutral |
May-16-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
Jan-06-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Jan-05-23 | Reiterated | H.C. Wainwright | Buy |
Nov-29-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Oct-24-22 | Downgrade | Piper Sandler | Overweight → Neutral |
Jul-05-22 | Downgrade | Evercore ISI | In-line → Underperform |
May-16-22 | Initiated | H.C. Wainwright | Buy |
Feb-08-22 | Initiated | Loop Capital | Buy |
Feb-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
Jan-20-22 | Upgrade | Truist | Hold → Buy |
Jan-03-22 | Upgrade | Evercore ISI | Underperform → In-line |
Jul-01-21 | Downgrade | Mizuho | Buy → Neutral |
Apr-14-21 | Downgrade | Wedbush | Neutral → Underperform |
Jan-25-21 | Reiterated | Piper Sandler | Overweight |
Sep-23-20 | Initiated | Northland Capital | Outperform |
Sep-18-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Sep-17-20 | Downgrade | Truist | Buy → Hold |
Jun-01-20 | Resumed | Oppenheimer | Perform |
May-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
Apr-09-20 | Downgrade | Evercore ISI | In-line → Underperform |
Mar-05-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
Jul-29-19 | Upgrade | SunTrust | Hold → Buy |
Jul-26-19 | Downgrade | JP Morgan | Overweight → Neutral |
Jul-26-19 | Downgrade | Wedbush | Outperform → Neutral |
Mar-20-19 | Initiated | SunTrust | Hold |
Nov-02-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
Jul-16-18 | Initiated | Evercore ISI | Outperform |
Apr-18-18 | Reiterated | Mizuho | Buy |
Feb-23-18 | Reiterated | Mizuho | Buy |
May-24-17 | Upgrade | Wells Fargo | Market Perform → Outperform |
Jul-29-16 | Reiterated | Wedbush | Outperform |
Jan-19-16 | Initiated | Barclays | Underweight |
Dec-02-15 | Initiated | Deutsche Bank | Hold |
View All
Novocure Ltd Stock (NVCR) Latest News
What was NovoCure Ltd (NVCR)’s performance in the last session? - US Post News
Evercore ISI Upgrades NovoCure Ltd (NVCR) to an Outperform from an In-line - Knox Daily
Financial Snapshot: Analyzing Spectral AI Inc (MDAI)’s Key Ratio Metrics - The Dwinnex
Ratio Examination: NovoCure Ltd (NVCR)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Exchange Traded Concepts LLC Has $859,000 Stock Holdings in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
NovoCure Ltd (NVCR) Should Be Considered Now, Despite A Loss Of -28.16% From High - Stocks Register
Nisa Investment Advisors LLC Grows Position in NovoCure Limited (NASDAQ:NVCR) - Defense World
Jim Cramer Likes This Tech Stock: 'Terrific Business, Niche Business' - Benzinga
Brokerages Set NovoCure Limited (NASDAQ:NVCR) PT at $32.67 - MarketBeat
NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
NovoCure Ltd (NASDAQ: NVCR): Overvalued In Comparison To Others? - Stocks Register
NovoCure (NASDAQ:NVCR) Stock Price Crosses Above 50-Day Moving AverageWhat's Next? - MarketBeat
Novocure Ltd. to Host Earnings Call - ACCESS Newswire
Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland - Yahoo Finance
Investing in NovoCure (NASDAQ:NVCR) a year ago would have delivered you a 85% gain - Yahoo Finance
Novocure gets approval for rooftop penthouse at downtown Portsmouth headquarters - AOL
FY2024 EPS Estimates for NovoCure Lifted by HC Wainwright - Defense World
HC Wainwright Increases Earnings Estimates for NovoCure - MarketBeat
NovoCure’s (NVCR) Buy Rating Reiterated at HC Wainwright - Defense World
HC Wainwright Forecasts NovoCure FY2029 Earnings - Defense World
Wedbush Has Positive Outlook of NovoCure FY2024 Earnings - Defense World
HC Wainwright Predicts NovoCure FY2029 Earnings - MarketBeat
Wedbush Comments on NovoCure's FY2024 Earnings (NASDAQ:NVCR) - MarketBeat
Novocure's COO Mukund Paravasthu sells $57,906 in shares By Investing.com - Investing.com South Africa
Novocure's COO Mukund Paravasthu sells $57,906 in shares - Investing.com India
NovoCure Ltd (NVCR) Shares Down 3.67% on Jan 14 - GuruFocus.com
NovoCure (NASDAQ:NVCR) Given Buy Rating at HC Wainwright - MarketBeat
Deep Dive Into NovoCure Stock: Analyst Perspectives (7 Ratings) - Benzinga
NovoCure’s (NVCR) Neutral Rating Reaffirmed at Wedbush - Defense World
NovoCure's (NVCR) Neutral Rating Reiterated at Wedbush - MarketBeat
Is Now The Time To Buy NovoCure Ltd (NASDAQ: NVCR) Stock? - Stocks Register
Novocure reports revenue growth, FDA approvals in 2024 - Investing.com India
Novocure Reports Strong 19% Revenue Growth, Hits $605M as Cancer Treatment Platform Expands - StockTitan
Investing in NovoCure (NASDAQ:NVCR) a year ago would have delivered you a 97% gain - Simply Wall St
NovoCure Limited (NASDAQ:NVCR) Shares Acquired by Versant Capital Management Inc - Defense World
NovoCure Limited (NASDAQ:NVCR) Receives $32.67 Average PT from Brokerages - MarketBeat
NovoCure Limited (NASDAQ:NVCR) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Novocure CEO to Present at J.P. Morgan Healthcare Conference, Announces Investor Meetings - StockTitan
Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference - Yahoo Finance
NovoCure Limited (NASDAQ:NVCR) Shares Acquired by Franklin Resources Inc. - MarketBeat
Geode Capital Management LLC Acquires 29,871 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World
NovoCure (NASDAQ:NVCR) Reaches New 12-Month HighShould You Buy? - MarketBeat
Research Analysts’ Recent Ratings Updates for NovoCure (NVCR) - Defense World
Novocure's SWOT analysis: oncology med-tech firm's stock faces growth challenges - Investing.com Australia
Tumor Treating Fields Market Growth in Future Scope 2024-2031 | Novocure GmbH and Zai Lab - openPR
Novocure's SWOT analysis: oncology med-tech firm's stock faces growth challenges By Investing.com - Investing.com South Africa
NovoCure (NASDAQ:NVCR) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World
Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio? - Benzinga
Novocure Stock Hits 52-Week High at $32.65 Amidst Strong Yearly Growth - Investing.com Australia
NovoCure (NASDAQ:NVCR) Shares Gap Up on Analyst Upgrade - MarketBeat
Novocure price target raised to $42 from $28 at Piper Sandler - Yahoo Finance
Novocure Ltd Stock (NVCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):